↓ Skip to main content

Novel Antischizophrenia Treatments

Overview of attention for book
Attention for Chapter 4: Towards medication-enhancement of cognitive interventions in schizophrenia.
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (73rd percentile)
  • Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

twitter
6 X users
facebook
1 Facebook page

Citations

dimensions_citation
23 Dimensions

Readers on

mendeley
58 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Towards medication-enhancement of cognitive interventions in schizophrenia.
Chapter number 4
Book title
Novel Antischizophrenia Treatments
Published in
Handbook of experimental pharmacology, October 2012
DOI 10.1007/978-3-642-25758-2_4
Pubmed ID
Book ISBNs
978-3-64-225757-5, 978-3-64-225758-2
Authors

Chou HH, Twamley E, Swerdlow NR, Hsun-Hua Chou, Elizabeth Twamley, Neal R. Swerdlow

Abstract

Current antipsychotic medications do little to improve real-life function in most schizophrenia patients. A dispassionate view of the dispersed and variable neuropathology of schizophrenia strongly suggests that it is not currently, and may never be, correctable with drugs. In contrast, several forms of cognitive therapy have been demonstrated to have modest but lasting positive effects on cognition, symptoms, and functional outcomes in schizophrenia patients. To date, attempts to improve clinical outcomes in schizophrenia by adding pro-cognitive drugs to antipsychotic regimens have had limited success, but we propose that a more promising strategy would be to pair drugs that enhance specific neurocognitive functions with cognitive therapies that challenge and reinforce those functions. By using medications that engage spared neural resources in the service of cognitive interventions, it might be possible to significantly enhance the efficacy of cognitive therapies. We review and suggest several laboratory measures that might detect potential pro-neurocognitive effects of drugs in individual patients, using a "test dose" design, aided by specific biomarkers predicting an individual's drug sensitivity. Lastly, we argue that drug classes viewed as "counter-intuitive" based on existing models for the pathophysiology of schizophrenia-including pro-catecholaminergic and NMDA-antagonistic drugs-might be important candidate "pro-cognitive therapy" drugs.

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 58 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Colombia 1 2%
Unknown 57 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 19%
Student > Ph. D. Student 10 17%
Student > Bachelor 7 12%
Student > Master 7 12%
Student > Doctoral Student 3 5%
Other 6 10%
Unknown 14 24%
Readers by discipline Count As %
Psychology 15 26%
Neuroscience 8 14%
Medicine and Dentistry 7 12%
Agricultural and Biological Sciences 5 9%
Nursing and Health Professions 3 5%
Other 5 9%
Unknown 15 26%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 March 2016.
All research outputs
#6,235,460
of 22,651,245 outputs
Outputs from Handbook of experimental pharmacology
#183
of 643 outputs
Outputs of similar age
#45,651
of 172,510 outputs
Outputs of similar age from Handbook of experimental pharmacology
#5
of 14 outputs
Altmetric has tracked 22,651,245 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 643 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.3. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 172,510 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.